Chemo and immunotherapy for locally advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding two types of immunotherapy (cemiplimab with either fianlimab or REGN7075) to standard chemotherapy is safe and effective for people with locally advanced rectal cancer that has not been treated before. It may help shrink the tumor enough to allow surgery that preserves the ability to control bowel movements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your rectal cancer has not spread to distant organs (like the liver or lungs).
- You have not had any previous chemotherapy, radiation, or other treatment for this cancer.
- Your rectal tumor is at a stage that makes surgery with sphincter sparing possible after neoadjuvant therapy.
- You have a type of rectal cancer called 'mismatch repair proficient' or 'microsatellite stable' (which means it does not have certain DNA repair defects).
- You are generally well enough to be up and about (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs (sintilimab and suvemcitug) to see if it can improve outcomes for patients with locally advanced rectal cancer that has not spread. The goal is to shrink the tumor before surgery, potentially making it easier to remove and reducing the risk of recurrence.
This trial tests a new combination for locally advanced rectal cancer: adding a cholesterol-lowering drug plus an immunotherapy drug to the standard chemotherapy and radiation before surgery. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (serplulimab) for people with rectal cancer that has spread to just a few spots in the body (no more than 5 tumors in up to 2 locations). It aims to see if this approach is safe and effective.
This trial tests a new combination of chemotherapy, radiation, and an immunotherapy drug called tislelizumab before surgery for rectal cancer that has grown locally. The goal is to see if this approach can shrink the tumor more effectively and improve surgical outcomes.
This trial tests a treatment plan that combines chemotherapy, radiation, and an immunotherapy drug before surgery for people with high-risk locally advanced rectal cancer. The goal is to see if this approach can improve outcomes.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.